What is the recommended treatment for tinea capitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment for Tinea Capitis

Organism-Directed First-Line Therapy is Essential

For Trichophyton species infections, use terbinafine as first-line therapy with weight-based dosing for 2-4 weeks; for Microsporum species infections, use griseofulvin for 6-8 weeks. 1, 2


Start Treatment Empirically Before Culture Results

  • Begin systemic antifungal therapy immediately if any cardinal clinical signs are present: scale, lymphadenopathy, alopecia, or kerion 1
  • Collect specimens via scalp scrapings, hair pluck, brush, or swab for microscopy and culture to confirm the organism 1, 2
  • Do not delay treatment while awaiting culture results in symptomatic patients 1

Trichophyton Species: Terbinafine First-Line

Weight-based dosing for terbinafine: 1, 2

  • Children <20 kg: 62.5 mg daily for 2-4 weeks
  • Children 20-40 kg: 125 mg daily for 2-4 weeks
  • Children >40 kg and adults: 250 mg daily for 2-4 weeks

Advantages of terbinafine: 1

  • Shorter treatment duration improves compliance
  • Fungicidal activity with superior efficacy against Trichophyton
  • Gastrointestinal disturbances and rashes occur in <8% of children

Critical caveat: Terbinafine fails against Microsporum species because it cannot be incorporated into hair shafts in prepubertal children and doesn't reach the scalp surface where arthroconidia are located 1


Microsporum Species: Griseofulvin First-Line

Dosing for griseofulvin: 1, 2, 3

  • Children <50 kg: 15-20 mg/kg/day for 6-8 weeks
  • Children >50 kg and adults: 1 g/day for 6-8 weeks

Key evidence: Eight weeks of griseofulvin is significantly more effective than 4 weeks of terbinafine for confirmed Microsporum infection 1

Common pitfall to avoid: Do not underdose griseofulvin—higher doses are needed due to increasing treatment failures with lower doses 1


Second-Line Options for Treatment Failure

If initial therapy fails, consider: 1, 2

  • Poor compliance
  • Suboptimal drug absorption
  • Organism insensitivity
  • Reinfection

Management algorithm: 1

  • If clinical improvement but positive mycology persists: Continue current therapy for an additional 2-4 weeks
  • If no clinical improvement: Switch to second-line therapy

Second-line agents: 1, 2

  • Itraconazole: 5 mg/kg/day for 2-4 weeks (effective against both Trichophyton and Microsporum species)
  • Fluconazole: Alternative for refractory cases with favorable tolerability profile and liquid formulation available

Mandatory Adjunctive Measures

Topical therapy: 1, 2

  • Use as adjunctive treatment only—never as monotherapy
  • Topical antifungals cannot eradicate scalp infections alone
  • Consider 2% ketoconazole or 1% selenium sulfide shampoo to reduce spore transmission

Screen and treat contacts: 1

  • Screen all family members and close contacts, especially for T. tonsurans infections
  • Cleanse hairbrushes and combs with bleach or 2% sodium hypochlorite solution

Special Clinical Scenarios

Kerion Management

Kerion is a fungal-driven inflammatory response, not a bacterial abscess: 1

  • Initiate oral systemic antifungal therapy immediately
  • Add topical or oral corticosteroids to alleviate severe inflammatory symptoms
  • Evaluate for secondary bacterial infection only when clinically indicated

Dermatophytid (Id) Reaction

Pruritic papular eruptions after starting antifungals represent a cell-mediated response to dying dermatophytes: 1, 2

  • Do not discontinue systemic antifungal therapy
  • Provide symptomatic relief with topical corticosteroids (or oral steroids in severe cases)
  • Continue the antifungal regimen

Favus (Chronic Variant)

Identify favus by yellow, cup-shaped crusted lesions ("scutula"): 1

  • Most often caused by Trichophyton schoenleinii
  • Can lead to scarring (cicatricial) alopecia if untreated
  • Exhibits characteristic fluorescence under Wood's lamp examination

Treatment Endpoint: Mycological Cure, Not Clinical Improvement

The definitive endpoint is mycological cure (negative microscopy and culture), not just clinical improvement: 1, 2

  • Repeat mycology sampling at the end of standard treatment period
  • Continue monthly sampling until mycological clearance is documented
  • Clinical relapse will occur if medication is not continued until the organism is eradicated 3

Monitoring and Safety

For terbinafine and itraconazole: 2

  • Monitor liver function, especially in patients with pre-existing hepatic abnormalities or prolonged therapy
  • Baseline liver function tests and complete blood count recommended before initiating therapy

Itraconazole drug interactions: 2

  • Contraindicated in heart failure
  • Significant interactions with warfarin, certain antihistamines, antipsychotics, midazolam, digoxin, and simvastatin

School Attendance

Children receiving appropriate systemic and adjunctive topical therapy can attend school or nursery: 1

  • Exclusion is impractical and unnecessary
  • Proper treatment reduces transmission risk

References

Guideline

Treatment of Tinea Capitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Antifungal Treatment for Tinea and Dermatophytes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.